Growth Metrics

Allurion Technologies (ALUR) Debt to Equity (2022 - 2024)

Allurion Technologies posted quarterly Debt to Equity of -$0.59 for Q1 2024, down 8.64% on a QoQ basis from -$0.54 in Q4 2023.

Allurion Technologies (ALUR) has 3 years of Debt to Equity data on file, last reported at -$0.59 in Q1 2024.

  • For the quarter ending Q1 2024, Debt to Equity changed N/A year-over-year to -$0.59; the trailing twelve-month figure through Mar 2024 stood at -$0.59 (changed N/A YoY), and the FY2023 full-year result was -$0.54, up 67.18% from the prior year.
  • Debt to Equity for Q1 2024 stood at -$0.59, down from -$0.54 in the prior quarter.
  • Across five years, Debt to Equity topped out at -$0.54 in Q4 2023 and bottomed at -$1.65 in Q4 2022.
  • The 3-year median for Debt to Equity is -$0.75 (2023), against an average of -$0.93.
  • Peak annual rise in Debt to Equity reached 67.18% in 2023, while the deepest fall reached 67.18% in 2023.
  • A 3-year view of Debt to Equity shows it stood at -$1.65 in 2022, then jumped by 67.18% to -$0.54 in 2023, then dropped by 8.64% to -$0.59 in 2024.
  • The last three Debt to Equity figures came in at -$0.59 (Q1 2024), -$0.54 (Q4 2023), and -$1.09 (Q3 2023), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Debt/Equity (Qtr)
1 Abbott Laboratories 152.82 Bn 146.17 Bn 6.27 Bn 0.65
2 Stryker 115.07 Bn 112.19 Bn 3.81 Bn 0.64
3 Medtronic 95.25 Bn 87.08 Bn 5.76 Bn 0.57
4 Boston Scientific 71.38 Bn 70.17 Bn 3.61 Bn 0.42
5 Edwards Lifesciences 51.08 Bn 47.41 Bn 1.29 Bn 0.06
6 Koninklijke Philips 29.38 Bn 26.07 Bn 2.07 Bn -
7 Dexcom 28.84 Bn 27.72 Bn 750.30 Mn -
8 GE HealthCare Technologies 28.56 Bn 26.49 Bn 1.98 Bn 0.95
9 Steris 20.71 Bn 20.30 Bn 697.10 Mn 0.27
10 Allurion Technologies - - 1.23 Mn -

Historic Data

Download Data 🔒
DateValue
Mar 31, 2024 -0.59
Dec 31, 2023 -0.54
Sep 30, 2023 -1.09
Jun 30, 2023 -0.75
Dec 31, 2022 -1.65